Gelesis Holdings Return on Investment 2021-2022 | GLS

Current and historical return on investment (ROI) values for Gelesis Holdings (GLS) over the last 10 years.
Gelesis Holdings ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-03-31 $-0.04B $0.04B 70.12%
2021-12-31 $-0.02B $-0.30B 24.41%
2021-06-30 $-0.02B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.114B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00